Pharmatec™ provides disease specific programs for patients undergoing treatment for chronic diseases such as Multiple Sclerosis, Rheumatoid Arthritis, Hepatitis C, Irritable Bowel Disease, and Infertility. Pharmatec™ supports the physician and practitioner/patient relationship and plan of care, by utilizing evidence-based guidelines and patient empowerment strategies. By working together to improve the overall health of patients, we reduce the cost of treatment. This is accomplished through:

• Evidenced based testing guidelines
• Evidenced based treatment guidelines
• Disease specific patient education
• Education directed at improvement of Health QOL indicators
• Education directed at improvement of General QOL indicators
• Provider education aimed at enhancing support of program goals
• Case management and clinical support
• Data collection of clinical and QOL outcome measures

This will lead to a return on investment by providing quality care in a cost-effective manner.

Approach to program development

• Thorough understanding of the diseases
• Identify cost drivers (Direct and Indirect Costs)
• Type of disease (Elective, Debilitating, Life-threatening)
• Type and number of medications
• Understanding of market forces (Medical/Pharmacy)
• Use available tools
• Focus on improving Health QOL indicators, General QOL indicators, and decreasing costs
• Measure program effect on Health QOL indicators, General QOL indicators and cost efficiencies through reporting

Value of integrating medical and pharmacy

• Provides a fuller understanding of the total cost of the disease (medical and pharmacy costs)
• Increases opportunities for patient identification
• Provides multiple points of intervention (e.g. medication persistence/compliance/utilization)
• Assures that the pharmacy and clinical DM program are working together to provide a comprehensive program
• Provides for better study of pharmacy intervention on clinical outcomes
• Provides for better study of clinical interventions on drug utilization